DRG Market Assessment reports

Introduction Alzheimer’s disease is a chronic disease than affects several million Brazilian and Mexican patients. Physicians have a small number of molecules available for the treatment of…

Anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for treating wet age-related macular degeneration (AMD), with several commercially available options. The continued…

The RSV therapy market is characterized by a large and growing population of people at risk of infection every year. At greatest risk are infants and the elderly. No interventions are approved for…

Diabetic macular edema (DME) associated with diabetic retinopathy (DR) is a rapidly evolving market as a result of multiple intravitreal pharmacotherapy product approvals across different drug…

Abstract: The psoriasis market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12…

The Hodgkin’s Lymphoma therapy market—currently dominated by multidrug chemotherapy regimens—will experience significant growth over the 2015-2025 forecast. This growth will be fueled by the…

The tumor necrosis factor alpha (TNF-a) inhibitors have set a high clinical standard for the treatment of psoriatic arthritis (PsA) that is challenging for emerging therapies to surpass. Meeting…

The United States has seen a dramatic rise in the prevalence of chronic kidney disease (CKD) and its sequelae—namely, diabetes and hypertension. Patients with CKD are typically co-managed by many…

The U.S. asthma therapy market has long been dominated by several effective and well-established treatments, including inhaled and oral therapies, but following the recent approval of two biologics…

The prevalence of spondyloarthritis is increasing in China, where the estimated number of total prevalent cases of ankylosing spondylitis (AS) exceeds 1.6 million. Although the total prevalence of…

LaunchTrends: Zarxio (Wave 2) is the second in a series of syndicated reports designed to track physician perception and uptake of Sandoz’s Zarxio (filgrastim-sndz), a biosimilar of Amgen’s…

Although agents available for controlling disease in mild ulcerative colitis (UC) are largely effective and well tolerated, many unmet needs exist in treating moderate to severe disease, and…